Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

AIDS and HIV Infection after Thirty Years.

Ippolito G, Levy JA, Sonnerborg A, Mugusi F, Dianzani F.

AIDS Res Treat. 2013;2013:731983. doi: 10.1155/2013/731983. Epub 2013 Jan 10. No abstract available.

2.

Nonspecific Defenses.

Dianzani F, Baron S.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 49.

3.

Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Riva E, Maggi F, Abbruzzese F, Bellomi F, Giannelli G, Picardi A, Scagnolari C, Folgori A, Spada E, Piccolella E, Dianzani F, Antonelli G; Acute Hepatitis C Italian Study Group.

Med Microbiol Immunol. 2009 Feb;198(1):13-8. doi: 10.1007/s00430-008-0099-9. Epub 2008 Aug 12.

PMID:
18696111
4.

Interferon may prevent HIV viral rebound after HAART interruption in HIV patients.

Dianzani F, Rozera G, Abbate I, D'Offizi G, Abdeddaim A, Vlassi C, Antonucci G, Narciso P, Martini F, Capobianchi MR.

J Interferon Cytokine Res. 2008 Jan;28(1):1-3. doi: 10.1089/jir.2007.0076.

PMID:
18370866
5.

Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.

D'Offizi G, Martini F, Rozera G, Abbate I, Capobianchi MR, Narciso P, Dianzani F.

AIDS. 2008 Jan 11;22(2):321. No abstract available.

PMID:
18097242
6.

What is the practical significance of antibodies to interferons?

Dianzani F, Antonelli G.

BioDrugs. 1998 Mar;9(3):187-95.

PMID:
18020559
7.

Markers of human papillomavirus infection and their correlation with cervical dysplasia in human immunodeficiency virus-positive women.

Riva E, Serraino D, Pierangeli A, Bambacioni F, Zaniratti S, Minosse C, Selleri M, Bucci M, Scagnolari C, Degener AM, Capobianchi MR, Antonelli G, Dianzani F; Roman Papillomavirus Study Group*.

Clin Microbiol Infect. 2007 Jan;13(1):94-7.

8.

Influence of GBV-C infection on the endogenous activation of the IFN system in HIV-1 co-infected patients.

Capobianchi MR, Lalle E, Martini F, Poccia F, D'Offizi G, Antonucci G, Abbate I, Dianzani F.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):3-8.

PMID:
16914092
9.

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V.

J Antimicrob Chemother. 2006 Jun;57(6):1055-64. Epub 2006 Apr 10.

PMID:
16606637
10.

Considerations on the development of serum antibodies to interferon-beta.

Antonelli G, Bagnato F, Dianzani F.

New Microbiol. 2005 Jul;28(3):183-92. Review.

PMID:
16240689
11.

Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders.

Abbate I, Cappiello G, Longo R, Ursitti A, Spanò A, Calcaterra S, Dianzani F, Antinori A, Capobianchi MR.

Infect Genet Evol. 2005 Apr;5(3):247-53. Epub 2004 Dec 7.

PMID:
15737916
12.

Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.

Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G.

Antivir Ther. 2004 Dec;9(6):1003-11.

PMID:
15651759
13.

Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.

Dianzani F, Frascione E.

Scand J Infect Dis Suppl. 2003;106:108-9. No abstract available.

PMID:
15000599
14.

Viral resistance to chemotherapeutic agents: an expectable unexpected phenomenon.

Dianzani F.

Scand J Infect Dis Suppl. 2003;106:6-7. Review. No abstract available.

PMID:
15000573
15.

Human immunodeficiency virus (HIV) DNA load and level of immunosuppression in treatment-naive HIV-1-infected patients.

Riva E, Antonelli G, Scagnolari C, Pistello M, Capobianchi MR, Monforte Ad, Pezzotti P, Dianzani F; I.CO.N.A. Study Group.

J Infect Dis. 2003 Jun 1;187(11):1826-8. No abstract available.

PMID:
12751043
16.

Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Scagnolari C, Casato M, Bellomi F, De Pisa F, Turriziani O, Coviello R, Pirro MR, Dianzani F, Antonelli G.

Clin Diagn Lab Immunol. 2003 Jan;10(1):70-7.

17.

Is human immunodeficiency virus RNA load composed of neutralized immune complexes?

Dianzani F, Antonelli G, Riva E, Turriziani O, Antonelli L, Tyring S, Carrasco DA, Lee H, Nguyen D, Pan J, Poast J, Cloyd M, Baron S.

J Infect Dis. 2002 Apr 15;185(8):1051-4. Epub 2002 Apr 1.

PMID:
11930314
18.

Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.

Riva E, Pistello M, Narciso P, D'Offizi G, Isola P, Galati V, Turriziani O, Tozzi V, Vincenzi L, Dianzani F, Antonelli G.

AIDS Res Hum Retroviruses. 2001 Nov 20;17(17):1599-604.

PMID:
11779347
19.

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.

Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A; Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group.

J Infect Dis. 2001 Oct 15;184(8):983-91. Epub 2001 Aug 30.

PMID:
11574912
20.

Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2.

Abbate I, Dianzani F, Turriziani O, Antonelli G, D'Offizi G, Galati V, Pierdominici M, Pandolfi F, Capobianchi MR.

AIDS. 2001 Jan 5;15(1):11-6.

PMID:
11192851
21.
22.

Cellular factors involved in the induction of resistance of HIV to antiretroviral agents.

Turriziani O, Antonelli G, Dianzani F.

Int J Antimicrob Agents. 2000 Nov;16(3):353-6.

PMID:
11091062
23.

Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group.

Rezza G, Lepri AC, d'Arminio Monforte A, Pezzotti P, Castelli F, Dianzani F, Lazzarin A, De Luca A, Arlotti M, Leoncini F, Manconi PE, Rizzardini G, Minoli L, Poggio A, Ippolito G, Phillips AN, Moroni M.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):56-62.

PMID:
11064505
24.

The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2. IRHAN Study Group.

Dianzani F, Antonelli G, Aiuti F, Turriziani O, Riva E, Capobianchi MR, Pandolfi F, D'Offizi G.

Antiviral Res. 2000 Feb;45(2):95-9.

PMID:
10809018
25.

Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy.

Riva E, Antonelli G, Solmone MC, Turriziani O, Narciso P, Tozzi V, Dianzani F.

J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):1-3.

PMID:
10763882
26.

May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?

Turriziani O, Di Marco P, Antonelli G, Dianzani F.

Antimicrob Agents Chemother. 2000 Feb;44(2):473-4. No abstract available.

27.

Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line.

Turriziani O, Simeoni E, Dianzani F, Antonelli G.

Antivir Ther. 1998;3(3):191-4.

PMID:
10682138
28.

Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle.

Savarino A, Bottarel F, Calosso L, Feito MJ, Bensi T, Bragardo M, Rojo JM, Pugliese A, Abbate I, Capobianchi MR, Dianzani F, Malavasi F, Dianzani U.

FASEB J. 1999 Dec;13(15):2265-76.

PMID:
10593874
29.

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.

Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F.

J Neurol Sci. 1999 Oct 15;168(2):131-6.

PMID:
10526196
30.

Chronic hepatitis B, biological basis for new therapeutic strategies.

Dianzani F.

J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):71-9. Review. No abstract available.

PMID:
10503729
31.

Development of antibodies to interferon beta in patients: technical and biological aspects.

Antonelli G, Dianzani F.

Eur Cytokine Netw. 1999 Sep;10(3):413-22. Review.

32.

RANTES stimulates cell-mediated transmission of HIV-1 infection.

Abbate I, Dianzani F, Bianchi F, Mosiello G, Carletti F, Fiumara D, Capobianchi MR.

J Interferon Cytokine Res. 1999 Apr;19(4):345-50.

PMID:
10334385
33.

Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies.

Viscomi GC, Antonelli G, Bruno C, Scapol L, Malavasi F, Funaro A, Simeoni E, Pestka S, De Pisa F, Dianzani F.

J Interferon Cytokine Res. 1999 Apr;19(4):319-26.

PMID:
10334382
34.

Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy.

Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L, Antonelli L, Pistello M, Dianzani F.

J Interferon Cytokine Res. 1999 Mar;19(3):243-51.

PMID:
10213463
35.

RANTES upregulation by HIV-1-infected cells: lack of correlation with viral replication and induction of interferon.

Abbate I, Carletti F, Dianzani F, Capobianchi MR.

AIDS. 1999 Feb 4;13(2):288-90. No abstract available.

PMID:
10202842
36.

Effects of IFN alpha on late stages of HIV-1 replication cycle.

Dianzani F, Castilletti C, Gentile M, Gelderblom HR, Frezza F, Capobianchi MR.

Biochimie. 1998 Aug-Sep;80(8-9):745-54.

PMID:
9865497
37.
38.

Resistance of HIV to antiretroviral agents. Basic concepts.

Dianzani F, Antonelli G, Turriziani O.

J Biol Regul Homeost Agents. 1998;12(1-2 Suppl):19-22. Review. No abstract available.

PMID:
9689574
39.

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, De Pisa F, Fieschi C, Gasperini C, Salvetti M, Dianzani F.

J Interferon Cytokine Res. 1998 May;18(5):345-50.

PMID:
9620362
40.

Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages.

Capobianchi MR, Abbate I, Antonelli G, Turriziani O, Dolei A, Dianzani F.

AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):233-40.

PMID:
9491913
42.

Induction of the multidrug-transporter P-glycoprotein by 3'-azido-3'-deoxythymidine (AZT) treatment in tumor cell lines.

Signoretti C, Romagnoli G, Turriziani O, Antonelli G, Dianzani F, Cianfriglia M.

J Exp Clin Cancer Res. 1997 Mar;16(1):29-32.

PMID:
9148857
43.

A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.

Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE, Ricciardulli D, Milazzo F, Gritti FM, Mazzotta F, Ranieri S, Chiodo F, Moroni M, Cargnel A, Bassetti D, Giannini V, Cremoni L, Concia E, Sinicco A, Carosi G, Alberici F, Dianzani F.

J Infect Dis. 1997 Feb;175(2):255-64.

PMID:
9203645
44.

Human immunodeficiency virus type 1 gp120 stimulates cytomegalovirus replication in monocytes: possible role of endogenous interleukin-8.

Capobianchi MR, Barresi C, Borghi P, Gessani S, Fantuzzi L, Ameglio F, Belardelli F, Papadia S, Dianzani F.

J Virol. 1997 Feb;71(2):1591-7.

45.

Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies.

Antonelli G, Simeoni E, Currenti M, De Pisa F, Colizzi V, Pistello M, Dianzani F.

Biotherapy. 1997;10(1):7-14. Review.

PMID:
9261545
46.

Further study of the mechanism underlying the cellular resistance to AZT.

Turriziani O, Antonelli G, Focher F, Bambacioni F, Dianzani F.

Biochem Biophys Res Commun. 1996 Nov 21;228(3):797-801.

PMID:
8941356
47.

A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.

Vella S, Floridia M, Dally LG, Tomino C, Fragola V, Weimer LE, Milazzo F, Mazzotta F, Moroni M, Pastore G, Scalise G, Sinicco A, Ortona L, De Rienzo B, Dianzani F.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 15;12(5):462-9.

PMID:
8757422
48.

Plasma HIV viremia and viral load in lymph nodes.

Dianzani F, Antonelli G, Riva E, Uccini S, Visco G.

Nat Med. 1996 Aug;2(8):832-3. No abstract available.

PMID:
8705839
49.

Interferon induction by HIV-1-infected cells: a possible role of sulfatides or related glycolipids.

Ankel H, Capobianchi MR, Frezza F, Castilletti C, Dianzani F.

Virology. 1996 Jul 1;221(1):113-9.

50.

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.

Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F.

Clin Exp Immunol. 1996 Jun;104(3):384-7.

Supplemental Content

Loading ...
Support Center